CTI BioPharma Corp. (GB:0RLB)

CTI BioPharma (0RLB) Share Price & Analysis


0RLB Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.65 - €0.65
Previous Close€0.65
Average Volume (3M)N/A
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$59.01M
Total Debt (Recent Filing)$48.08M
Price to Earnings (P/E)-1.2
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding131,880,176
10 Day Avg. Volume217
30 Day Avg. VolumeN/A
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)15.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside1267.85% Upside
Rating ConsensusHold
Number of Analyst Covering7




What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest share price was €0.65 and its highest was €0.65 in the past 12 months.
    What is CTI BioPharma Corp.’s market cap?
    Currently, no data Available
    When is CTI BioPharma Corp.’s upcoming earnings report date?
    CTI BioPharma Corp.’s upcoming earnings report date is Aug 03, 2023 which is 120 days ago.
      How were CTI BioPharma Corp.’s earnings last quarter?
      CTI BioPharma Corp. released its earnings results on May 11, 2023. The company reported -€0.091 earnings per share for the quarter, beating the consensus estimate of -€0.104 by €0.013.
        Is CTI BioPharma Corp. overvalued?
        According to Wall Street analysts CTI BioPharma Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does CTI BioPharma Corp. pay dividends?
          CTI BioPharma Corp. does not currently pay dividends.
          What is CTI BioPharma Corp.’s EPS estimate?
          CTI BioPharma Corp.’s EPS estimate is -€0.07.
            How many shares outstanding does CTI BioPharma Corp. have?
            Currently, no data Available
            What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
            CTI BioPharma Corp. reported an EPS of -€0.091 in its last earnings report, beating expectations of -€0.104. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of CTI BioPharma Corp.?
              Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.


                Company Description

                CTI BioPharma Corp.

                CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                CytomX Therapeutics
                Kala Pharmaceuticals
                Adamis Pharma
                G1 Therapeutics
                CTI BioPharma

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis